The FDA has granted a breakthrough therapy designation to LOXO-292 for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options.
Oncologist Kelly McCann, MD, PhD, reviews the vast improvements in the treatment landscape for patients with HER2-positive breast cancer, as well as the work that lies ahead.
Helena A. Yu, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, explains the implications of the approval of osimertinib as the frontline standard of care for patients with EGFR-mutant non–small cell lung cancer.
Therapeutic strategies for treating less-common molecular targets found in non–small cell lung cancer (NSCLC), such as ROS1, NTRK, MET, and HER2, are under development.
Three CDK 4/6 inhibitors—palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio)— are game-changers in the field of breast cancer, explained Richard S. Finn, MD.
Expert Jeffrey Lancet, MD, discusses the emerging agents in treating acute myeloid leukemia (AML) and challenges that still exist for improving patient outcome.
Even if a patient is being treated for melanoma, they should still be getting examined for new primary melanomas, as well as skin-related adverse events.
Patients with lung cancer who received low-dose CT scans had a 15% to 20% lower risk of death from their disease versus those who had standard chest X-rays, which has led to screening guidelines.
Inaccurate ideas of palliative care can negative effect the outcomes for patients with lung cancer.
There are specific challenges when treating AYA patients with Hodgkin lymphoma.
For BRCA1/2 and other genes, it is important that practitioners begin testing for heriditary genes for ovarian cancers.
Expert Joyce O'Shaughnessy discusses current topics in breast cancer, particular the advances and future for triple-negative breast cancer (TNBC).
Expert Michael Morris, MD, discusses the current and future role of radium-223 dichloride in treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Stem cell transplant remains to be a curative and reliable strategy for multiple myeloma and other hematologic malignancies.
Tanya Dorff, MD, explains the developments of chemotherapy in firstline treatment for hormone-sensitive metastatic prostate cancer as well as personalized treatment in this population.
Somatostatin analog lanreotide (Somatuline Depot) is being considered for patients with lung neuroendocrine tumors (NETs) in a potentially practice-changing clinical trial.
Patients undergoing Androgen-deprivation therapy (ADT) for prostate cancer may be at risk of significant psychological effects.
New practice guideline now recommends a 2-mm margin width as the standard for patients with DCIS undergoing breast-conserving surgery.
Despite some advances in treatment options for patients with sarcomas, researchers are still actively seeking to improve outcomes for pediatric, adolescent and young adult patients, a group particularly impacted by this diagnosis.
Using an individualized approach to decide whether asymptomatic women under age 50 should have mammograms is at the center of the final screening guidelines published by the US Preventive Services Task Force (USPSTF), but the group
For patients with epithelial ovarian cancer, adjuvant hormone therapy (AHT) proved to be safe and reduced the risk of death by 37%, according to findings of a 24-year study recently published in the Journal of Clinical Oncology.
With today's approximately 14.5 million cancer survivors-a number projected to reach nearly 18 million in 2024-new survivorship models of care are needed.
